INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc.
The investigation concerns whether Adverum and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On March 31, 2025, Adverum disclosed in a filing with the U.S. Securities and Exchange Commission that 'certain of the Company's previously issued financial statements should no longer be relied upon due to non-cash errors identified in the accounting for tenant improvement allowances associated with an operating lease and sublease related to a building in North Carolina (the 'NC Premises').' Accordingly, Adverum announced that it will restate its 'financial statements as of and for the years ended December 31, 2022 and 2023, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 . . . , as well as the unaudited condensed consolidated quarterly financial information for the quarterly periods in the years ended December 31, 2023 and 2024.'
On this news, Adverum's stock price fell $0.54 per share, or 12.36% to close at $3.83 per share on April 1, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a minute ago
- Business Wire
Deadline Alert: KinderCare Learning Companies, Inc. (KLC) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP reminds investors of the upcoming deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired KinderCare Learning Companies, Inc. ('KinderCare' or the 'Company') (NYSE: KLC) common stock pursuant and/or traceable to the Company's October 2024 initial public offering (the 'IPO'). IF YOU SUFFERED A LOSS ON YOUR KINDERCARE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? In October of 2024, KinderCare conducted its IPO, selling over 27 million shares of common stock at $24 per share. On April 3, 2025, the Bear Cave published a report alleging, among other things, that KinderCare 'fails to deliver the safe and nurturing environment it promises parents and taxpayers' and is 'a broken business that harms the children and families it claims to help.' Specifically, the report detailed several incidents of child neglect and abuse that had occurred at KinderCare daycares and stated that on several occasions, individuals employed by KinderCare were later arrested on charges of child sex abuse. On this news, KinderCare's stock price fell $1.59, or 12.4%, to close at $11.19 per share on April 3, 2025, thereby injuring investors. Then, on June 5, 2025, the Bear Cave published a second report stating that 'allegations against [KinderCare] are growing, [and] lawmakers are demanding accountability.' Specifically, the report cited a statement from a congresswoman questioning the continued federal funding of KinderCare. On this news, KinderCare's stock price fell $0.63, or 5.5%, to close at $10.78 per share on June 5, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Registration Statement, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that numerous incidents of child abuse, neglect, and harm had occurred at KinderCare facilities; (2) that KinderCare did not provide the 'highest quality care possible' at its facilities, and, indeed, in numerous instances had failed to provide even basic care, meet minimum standards in the child care industry, or comply with the laws and regulations governing the care of children; (3) that, as a result of the foregoing, KinderCare was exposed to a material, undisclosed risk of lawsuits, adverse regulatory action, negative publicity, reputational damage, and business loss; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired KinderCare common stock pursuant and/or traceable to the IPO, you may move the Court no later than October 14, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150, Toll-Free: 888-773-9224 Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. If you inquire by email, please include your mailing address, telephone number and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Associated Press
2 minutes ago
- Associated Press
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortinet, Inc.
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fortinet, Inc. ('Fortinet' or the 'Company') (NASDAQ: FTNT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Fortinet and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 6, 2025, Fortinet reported disappointing second quarter 2025 financial results. In response, Investor's Business Daily quoted William Blair analyst Jonathan Ho as stating, 'Investors were left confused by the company's formal statement that 40% to 50% of its accelerated firewall refresh (estimated to be a $450 million, 650,000 unit opportunity) was now completed. This is driving confusion about why Fortinet is not seeing stronger product revenue growth and billings materialize.' On this news, Fortinet's stock price fell $21.28 per share, or 22.03%, to close at $75.30 per share on August 7, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980
Associated Press
2 minutes ago
- Associated Press
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sensus Healthcare, Inc.
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. ('Sensus' or the 'Company') (NASDAQ: SRTS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Sensus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 7, 2025, Sensus reported its financial results for the second quarter of 2025, revealing a second quarter GAAP earnings-per-share figure of -$0.06, missing estimates by $0.09, and revenue of $7.3M, representing a -20.7% year-over-year decline and missing estimates by $2M. Sensus attributed the decrease in revenue primarily to a lower number of units sold to a large customer, partially offset by growth in recurring revenue from Fair Deal Agreements. On this news, Sensus's stock price fell $1.89 per share, or 35.32%, to close at $3.46 per share on August 8, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980
